Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique

QR Code

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique

Abstract Background For lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) sensitive mutation and synchronous brain metastasis (syn‐BM), when and how to apply radiotherapy (RT) during first‐line tyrosine kinase inhibitor (TKI) treatment remains debatable. Methods From a real‐w...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Yangchun Gu, Yan Xu, Hongqing Zhuang, Weijuan Jiang, Hua Zhang, Xiaofeng Li, Yonggang Liu, Li Ma, Dahai Zhao, Yuan Cheng, Yan Yu, Ping Liu, Jianwen Qin, Xueqin Chen, Junzhen Gao, Mengzhao Wang, Li Liang, Baoshan Cao
Format:	article
Langue:	EN
Publié:	Wiley 2021
Sujets:	brain metastasis EGFR mutation EGFR‐TKIs lung adenocarcinoma radiation therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/13557e99f1774b2fab8474230466f55f
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
par: Chaido Sirinian, et autres
Publié: (2021)

Effect of brain radiotherapy strategies on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
par: Guangchuan Deng, et autres
Publié: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
par: Gan J, et autres
Publié: (2021)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
par: Akiko Takahashi, et autres
Publié: (2018)

Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
par: Kim JS, et autres
Publié: (2018)

Identification of Six Prognostic Genes in EGFR–Mutant Lung Adenocarcinoma Using Structure Network Algorithms
par: Haomin Zhang, et autres
Publié: (2021)

Experience of Uncommon EGFR Mutation in Lung Scheme Quality Program: Discussing Risks and Opportunities for the Improvement of Laboratory Response
par: Alessandro Pancrazzi, et autres
Publié: (2021)

Inhibition of EGFR Signaling Protects from Mucormycosis
par: Tonya N. Watkins, et autres
Publié: (2018)

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
par: Chin‐Chou Wang, et autres
Publié: (2021)

Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
par: Jiang WT, et autres
Publié: (2018)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
par: Yurong Wang, et autres
Publié: (2021)

Cellular Origins of EGFR‐Driven Lung Cancer Cells Determine Sensitivity to Therapy
par: Fan Chen, et autres
Publié: (2021)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
par: Kate S, et autres
Publié: (2019)

eGFRs from Asian-modified CKD-EPI and Chinese-modified CKD-EPI equations were associated better with hypertensive target organ damage in the community-dwelling elderly Chinese: the Northern Shanghai Study
par: Ji H, et autres
Publié: (2017)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
par: Taichi Miyawaki, et autres
Publié: (2021)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
par: Yang W, et autres
Publié: (2020)

Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer
par: Cristina Minnelli, et autres
Publié: (2021)

Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion
par: Kunyan He, et autres
Publié: (2021)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
par: Diana B. Peckys, et autres
Publié: (2021)

SIGNIFICANCE OF RENAL FUNCTION IN TRAUMA: AN OBSERVATIONAL STUDY TO ASCERTAIN CORRELATION TO EGFR
par: Syed Faraz Ahmed, et autres
Publié: (2020)

EGFR-targeted photodynamic therapy by curcumin-encapsulated chitosan/TPP nanoparticles
par: Tsai WH, et autres
Publié: (2018)

Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
par: Tomasz Marjanski, et autres
Publié: (2021)

Canine parvovirus induces G1/S cell cycle arrest that involves EGFR Tyr1086 phosphorylation
par: Xiaofeng Dai, et autres
Publié: (2020)

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
par: Mohammed A. S. Abourehab, et autres
Publié: (2021)

Affibody-Modified Gd@C-Dots with Efficient Renal Clearance for Enhanced MRI of EGFR Expression in Non-Small-Cell Lung Cancer
par: Wu Y, et autres
Publié: (2020)

Design of New Quinazoline Derivative as EGFR (Epidermal Growth Factor Receptor) Inhibitor through Molecular Docking and Dynamics Simulation
par: Herlina Rasyid, et autres
Publié: (2020)

Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles
par: Grapa CM, et autres
Publié: (2019)

Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
par: Oh F, et autres
Publié: (2018)

ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί
par: Jeon-Soo Lee, et autres
Publié: (2021)

Lamellipodin-RICTOR Signaling Mediates Glioblastoma Cell Invasion and Radiosensitivity Downstream of EGFR
par: Stefanie Moritz, et autres
Publié: (2021)

KIF15 Promotes Progression of Castration Resistant Prostate Cancer by Activating EGFR Signaling Pathway
par: Lin Gao, et autres
Publié: (2021)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
par: Elli Narvi, et autres
Publié: (2018)

ANALYSIS OF IMMUNOHISTOCHEMICAL EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) IN COLORECTAL CANCER
par: Ghazala Sadaf, et autres
Publié: (2020)

circ_CHFR regulates ox-LDL-mediated cell proliferation, apoptosis, and EndoMT by miR-15a-5p/EGFR axis in human brain microvessel endothelial cells
par: Wu Shanwu, et autres
Publié: (2021)

RUNX1/EGFR pathway contributes to STAT3 activation and tumor growth caused by hyperactivated mTORC1
par: Wei Lin, et autres
Publié: (2021)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
par: Zhang SS, et autres
Publié: (2021)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
par: Santarpia M, et autres
Publié: (2017)

Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases
par: Seung-Uon Shin, et autres
Publié: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
par: Whitney E. Lewis, PharmD, et autres
Publié: (2021)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
par: Alexey A. Bogdanov, et autres
Publié: (2021)